Literature DB >> 26732943

Radiation risk models for all solid cancers other than those types of cancer requiring individual assessments after a nuclear accident.

Linda Walsh1,2, Wei Zhang3.   

Abstract

In the assessment of health risks after nuclear accidents, some health consequences require special attention. For example, in their 2013 report on health risk assessment after the Fukushima nuclear accident, the World Health Organisation (WHO) panel of experts considered risks of breast cancer, thyroid cancer and leukaemia. For these specific cancer types, use was made of already published excess relative risk (ERR) and excess absolute risk (EAR) models for radiation-related cancer incidence fitted to the epidemiological data from the Japanese A-bomb Life Span Study (LSS). However, it was also considered important to assess all other types of solid cancer together and the WHO, in their above-mentioned report, stated "No model to calculate the risk for all other solid cancer excluding breast and thyroid cancer risks is available from the LSS data". Applying the LSS models for all solid cancers along with the models for the specific sites means that some cancers have an overlap in the risk evaluations. Thus, calculating the total solid cancer risk plus the breast cancer risk plus the thyroid cancer risk can overestimate the total risk by several per cent. Therefore, the purpose of this paper was to publish the required models for all other solid cancers, i.e. all solid cancers other than those types of cancer requiring special attention after a nuclear accident. The new models presented here have been fitted to the same LSS data set from which the risks provided by the WHO were derived. Although it is known already that the EAR and ERR effect modifications by sex are statistically significant for the outcome "all solid cancer", it is shown here that sex modification is not statistically significant for the outcome "all solid cancer other than thyroid and breast cancer". It is also shown here that the sex-averaged solid cancer risks with and without the sex modification are very similar once breast and thyroid cancers are factored out. Some other notable model differences between those already published for all solid cancers and those presented here for all other solid cancers are also given here. The models presented here can be used to improve on the methodology adopted by WHO after Fukushima and could contribute to emergency preparedness for future nuclear accidents.

Entities:  

Keywords:  Fukushima risk assessment; Japanese A-bomb survivors; Radiation epidemiology; Risk models

Mesh:

Year:  2016        PMID: 26732943     DOI: 10.1007/s00411-015-0629-y

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  11 in total

1.  On the conversion of solid cancer excess relative risk into lifetime attributable risk.

Authors:  A M Kellerer; E A Nekolla; L Walsh
Journal:  Radiat Environ Biophys       Date:  2001-12       Impact factor: 1.925

2.  Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors.

Authors:  Albrecht M Kellerer; Werner Rühm; Linda Walsh
Journal:  Health Phys       Date:  2006-06       Impact factor: 1.316

3.  Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from γ-ray and neutron absorbed doses with hierarchical partitioning.

Authors:  Linda Walsh
Journal:  Radiat Environ Biophys       Date:  2012-11-17       Impact factor: 1.925

4.  A framework for estimating radiation-related cancer risks in Japan from the 2011 Fukushima nuclear accident.

Authors:  L Walsh; W Zhang; R E Shore; A Auvinen; D Laurier; R Wakeford; P Jacob; N Gent; L R Anspaugh; J Schüz; A Kesminiene; E van Deventer; A Tritscher; M del Rosarion Pérez
Journal:  Radiat Res       Date:  2014-09-24       Impact factor: 2.841

5.  Worker doses and potential health effects resulting from the accident at the Fukushima nuclear power plant in 2011.

Authors:  George Etherington; Wei Zhang; John Harrison; Linda Walsh
Journal:  Int J Radiat Biol       Date:  2014-11       Impact factor: 2.694

6.  Studies of the mortality of atomic bomb survivors, Report 14, 1950-2003: an overview of cancer and noncancer diseases.

Authors:  Kotaro Ozasa; Yukiko Shimizu; Akihiko Suyama; Fumiyoshi Kasagi; Midori Soda; Eric J Grant; Ritsu Sakata; Hiromi Sugiyama; Kazunori Kodama
Journal:  Radiat Res       Date:  2011-12-15       Impact factor: 2.841

7.  Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates.

Authors:  Dale L Preston; Donald A Pierce; Yukiko Shimizu; Harry M Cullings; Shoichiro Fujita; Sachiyo Funamoto; Kazunori Kodama
Journal:  Radiat Res       Date:  2004-10       Impact factor: 2.841

8.  Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997.

Authors:  Dale L Preston; Yukiko Shimizu; Donald A Pierce; Akihiko Suyama; Kiyohiko Mabuchi
Journal:  Radiat Res       Date:  2003-10       Impact factor: 2.841

9.  Solid cancer incidence in atomic bomb survivors: 1958-1998.

Authors:  D L Preston; E Ron; S Tokuoka; S Funamoto; N Nishi; M Soda; K Mabuchi; K Kodama
Journal:  Radiat Res       Date:  2007-07       Impact factor: 2.841

Review 10.  Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987.

Authors:  D E Thompson; K Mabuchi; E Ron; M Soda; M Tokunaga; S Ochikubo; S Sugimoto; T Ikeda; M Terasaki; S Izumi
Journal:  Radiat Res       Date:  1994-02       Impact factor: 2.841

View more
  1 in total

1.  Thyroid Cancer Following Childhood Low-Dose Radiation Exposure: A Pooled Analysis of Nine Cohorts.

Authors:  Jay H Lubin; M Jacob Adams; Roy Shore; Erik Holmberg; Arthur B Schneider; Michael M Hawkins; Leslie L Robison; Peter D Inskip; Marie Lundell; Robert Johansson; Ruth A Kleinerman; Florent de Vathaire; Lena Damber; Siegal Sadetzki; Margaret Tucker; Ritsu Sakata; Lene H S Veiga
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.